These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1048 related articles for article (PubMed ID: 17112329)

  • 21. Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
    Briseño GG; Mino-León D
    Curr Med Res Opin; 2010 May; 26(5):1075-81. PubMed ID: 20225991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
    Rublee DA; Burke JP
    Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
    MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
    Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
    Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice.
    Gandhi SK; Järbrink K; Fox KM; Brandrup-Wognsen G
    Curr Med Res Opin; 2009 Dec; 25(12):2817-28. PubMed ID: 19916726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF; Kastelein JJ;
    Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
    Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
    Betteridge DJ; Gibson JM; Sager PT
    Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
    Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E;
    Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
    Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C; Ruff L; Balu S
    J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
    Ohsfeldt RL; Gandhi SK; Fox KM; McKenney JM
    Value Health; 2008 Dec; 11(7):1061-9. PubMed ID: 18489494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
    Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.